Targeting prostaglandin E EP receptors to inhibit metastasis.

@article{Fulton2006TargetingPE,
  title={Targeting prostaglandin E EP receptors to inhibit metastasis.},
  author={Amy M Fulton and Xinrong Ma and Namita Kundu},
  journal={Cancer research},
  year={2006},
  volume={66 20},
  pages={
          9794-7
        }
}
It is well established that high cyclooxygenase-2 (COX-2) expression contributes to the aggressive behavior of breast and other malignancies. Due to concerns regarding the safety of long-term use of COX-2 inhibitors as well as a desire to seek more effective alternatives to prevent and treat metastatic disease, we tested the hypothesis that inhibition of downstream signaling by the COX-2 product prostaglandin E(2) (PGE(2)) would be as effective as inhibiting global prostaglandin synthesis. PGE… 
View on PubMed
cancerres.aacrjournals.org
132 Citations
Highly Influential Citations
3
Background Citations
49
Methods Citations
2

Figures from this paper

132 Citations

Citation Type

Citation Type

Prostaglandin E2 EP receptors as therapeutic targets in breast cancer
TLDR
While preclinical and epidemiological data support the use of nonsteroidal anti-inflammatory drugs and selective COX-2 inhibitors (COXibs) for the prevention and treatment of malignancy, toxicities due to COXIBs as well as less than promising results from clinical trials have laboratories seeking alternative targets.
Molecular inhibition of prostaglandin E2 with GW627368X: Therapeutic potential and preclinical safety assessment in mouse sarcoma model
TLDR
The results assert the significance of EP4 prostanoid receptor as a therapeutic target as well as the safety of EP3 blockade by GW627368X and the safety profile of the drug was analyzed.
Tumor-growth-promoting cyclooxygenase-2 prostaglandin E2 pathway provides medulloblastoma therapeutic targets.
TLDR
It is suggested that PGE(2) is important for MB growth and that therapies targeting the prostanoid metabolic pathway are potentially beneficial and should be tested in clinical settings for treatment of children with MB.
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
TLDR
These studies support the continued investigation of EP4 as a potential therapeutic target and provide new insight regarding the role ofEP4 in supporting a breast cancer stem cell/tumor-initiating phenotype.
Prostaglandin E receptor EP4 is a therapeutic target in breast cancer cells with stem-like properties
TLDR
Mammo-sphere-forming breast cancer cells of human origin of basal-type,Her-2 phenotype and/or with heightened metastaticcapacity upregulate expression of both EP4 and COX-2 and are more tumorigenic compared to the bulk population.
EP3 (prostaglandin E2 receptor 3) expression is a prognostic factor for progression-free and overall survival in sporadic breast cancer
TLDR
In sporadic breast cancer, EP3 receptor expression is not significantly associated with clinicopathological parameters but is a significant prognostic factor for improved progression-free and overall survival.
A prostaglandin E (PGE) receptor EP4 antagonist protects natural killer cells from PGE2-mediated immunosuppression and inhibits breast cancer metastasis
TLDR
The findings reveal that EP4 antagonism prevents tumor-mediated NK-cell immunosuppression and demonstrates the anti-metastatic activity of a novel EP4 antagonist, which support the investigation of EP4 antagonists in clinical trials.
Prostaglandin E Receptor EP1 Suppresses Breast Cancer Metastasis and Is Linked to Survival Differences and Cancer Disparities
TLDR
The hypothesis that EP1 functions as a metastasis suppressor and that loss of nuclear EP1 is associated with poorer overall survival is supported and may contribute to disparities in outcome in different populations.
Host prostaglandin EP3 receptor signaling relevant to tumor-associated lymphangiogenesis.
Prostaglandin E2 as a potent therapeutic target for treatment of colon cancer.
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 41 REFERENCES
Prostaglandin E receptor EP4 antagonism inhibits breast cancer metastasis.
TLDR
The hypothesis that EP receptor antagonists may be an alternative approach to the use of COX inhibitors to prevent tumor metastasis is supported.
Role of the Prostaglandin E 2 Receptor in Mammary Tumor Metastasis 1
TLDR
It is shown that three agents antagonize |'H|PGE2 binding to these cells and block PGE2mediated elevation of intracellular cyclic AMP, which contributes to the ability of murine mammary tumor cells to metastasize.
Involvement of prostaglandin E receptor subtype EP(4) in colon carcinogenesis.
TLDR
Results indicate that PGE(2) contributes to colon carcinogenesis through its actions mediated through EP(1) and EP(4) receptors; therefore, antagonists for these two receptors may be good candidates as chemopreventive agents against colon cancer.
Role of the prostaglandin E2 receptor in mammary tumor metastasis.
TLDR
The tumor cell PGE2 receptor contributes to the ability of murine mammary tumor cells to metastasize, and three agents, LEO101, SC19220, and AH6809 are shown to antagonize [3H]PGE2 binding to these cells and block P GE2-mediated elevation of intracellular cyclic AMP.
Chemopreventive effects of ONO-8711, a selective prostaglandin E receptor EP(1) antagonist, on breast cancer development.
TLDR
It is suggested that EP( 1) receptor is associated with breast cancer development and selective PGE receptor EP(1) antagonists may possess chemopreventive effects through the induction of apoptosis without any side effects.
The prostaglandin E2 receptor EP2 is required for cyclooxygenase 2-mediated mammary hyperplasia.
TLDR
Data suggest that PGE2 signaling via the EP2 receptor in mammary epithelial cells regulate mammary gland hyperplasia by the cAMP-dependent induction of amphiregulin.
Role of prostaglandin E2 receptors in migration of murine and human breast cancer cells.
Colon Carcinoma Cell Growth Is Associated with Prostaglandin E2/EP4 Receptor-evoked ERK Activation*
TLDR
The observation that indomethacin increases the survival rates of tumor-bearing mice, even after withdrawal of the drug, indicates that its effects are long lasting and that it may be potentially useful for the prevention and the clinical management of human cancers.
Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells.
TLDR
It is reported that PGE2 treatment of human colon cancer cells leads to increased clonogenicity of HCA-7, but not HCT-116 cells, which may help to explain a component of the mechanism by which COX inhibitors prevent colorectal cancer in humans.
Prostaglandin E2 regulates aromatase activity and expression in human adipose stromal cells via two distinct receptor subtypes.
TLDR
The results demonstrate that regulation of aromatase by PGE(2) is complex and may influence the development and progression of hormone-dependent breast cancer.
...
1
2
3
4
5
...